טוען...
Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
BACKGROUND: Fibroblast growth factor 21 (FGF21) is an endocrine-acting hormone that has the potential to treat diabetic nephropathy. However, development of FGF21 into a therapeutic has been hindered due to its low intrinsic bio-stability. In our previous study, we have developed a recombinant human...
שמור ב:
| הוצא לאור ב: | BMC Biotechnol |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5496364/ https://ncbi.nlm.nih.gov/pubmed/28676059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12896-017-0368-z |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|